Announcements

Mr. Rahul Guha has taken charge as the Managing Director & Chief Executive Officer with effect from Wednesday, May 04, 2022. Mr. Rahul Guha will also function as the Managing Director & CEO of Nueclear Healthcare Limited, our wholly owned subsidiary. Mr. Dharmil Sheth, who was appointed as the Managing Director for the interim period to comply with the provisions of Sec. 203 (4) of the Companies Act, 2013, has demitted office effective from Wednesday, May 04, 2022 and will continue to be a Non-Executive, Non-Independent Director of the Company.Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company’s financial results for Quarter / Whole year ended March 31, 2022, on Friday, May 06, 2022 at 04.00 p.m. local time.Investorscallrevised

We wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company’s financial results for Quarter / Whole year ended March 31, 2022, on Friday, May 06, 2022 at 04.00 p.m. local time.

Mr. Rahul Guha, MD & CEO Designate, who will take charge tomorrow, the 4^th May 2022, and Mr. Sachin Salvi, Chief Financial Officer, will represent the Company .Investorscall

Presentation on Audited Financial Results for the quarter / whole year ended 31-03-2022InvestorsPresentation31032022

Intimation of decisions taken at the Board Meeting held on April 29, 2022, about approved the Audited Financial Results (Stand-alone and Consolidated) for the Financial Year ended March 31, 2022 and have also decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. The Board has fixed, Thursday 12^th May 2022 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend.

Intimation about Board Meeting scheduled to be held on Friday, April 29 ,2022 inter alia, to consider and approve the audited financial results (both Stand-alone and Consolidated) for the quarter / Financial year ended 31st March 2022.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from April 01, 2022, and would be re-opened after 48 hours of date of announcement / declaration of Audited Financial Results for the Financial Year ended March 31, 2022

Pursuant to Regulation 30 and Regulation 31(8)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has received approval from the National Stock Exchange of India and BSE Ltd. for reclassification of the outgoing Promoters and Promoter Group shareholders from Promoter category to to public category in accordance with the Regulation 31A (10) of SEBI (Listing and Disclosure requirements), Regulation 2015. https://investor.thyrocare.com/wp-content/uploads/2022/03/IntimationtoNSEandBSEforapprovalofreclassficationofshares.pdf

Presentation – Unaudited financial results for the quarter/nine months period ended 31-12-2021.https://investor.thyrocare.com/wp-content/uploads/2022/03/Presentationupdate.pdf

Intimation of decision taken at the Board Meeting held on February 12, 2022 to approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine months ended December 31, 2021, and appointed Mr. Dharmil Sheth as Managing Director with effect from 12-02-2022 till the time Mr. Rahul Guha takes charge as MD and CEO.

The Board of Directors have, in order to comply with the provisions of Sub-Section 4 of Section 203 of the Companies Act, 2013, appointed Mr. Dharmil Sheth, presently a non-independent, non-executive director, to hold the position of Managing Director with effect from 12-02-2022 till the time Mr. Rahul Guha takes charge as MD and CEO.

Intimation about Board Meeting scheduled to be held on Saturday, February 12,2022 inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / nine months ended 31st December 2021.

Press Release being issued by the Company for the appointment of Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the Company. Enclosed press release:https://investor.thyrocare.com/wp-content/uploads/2022/02/Epic-Press-Release.docx-3.pdf

The Board of Directors of the Company, at their meeting held on Saturday, 05^th February, 2022, have approved appointment of  Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the Company. He will be joining by May 2022.

The Board of Directors of the Company, at their meeting held on January 28, 2022, based on the recommendations of the Nomination & Remuneration Committee and Audit Committee, have appointed Mr. Sachin Salvi, presently working as Senior Vice President – Finance as the Chief Financial Officer of the Company with effect from January 28, 2022.

Intimation of decision taken at the Board Meeting held on January 28, 2022 to approve the following Special Purpose Interim Consolidated financial statements – For the period 1st April to 30th November 2021 and for the stub period 2nd September to 30th November 2021. Approved the Restated financial statements for the stub period 2nd September to 30th November 2021.The Board has appointed Mr. Sachin Salvi, presently working as Senior Vice-President-Finance, as Chief Financial Officer of the Company effective from today, 28^th January 2022

Intimation of decision taken at the Board Meeting held on January 10, 2022 for approval for sharing financials statements for the period 1st April to 30th September 2021, For the period 1st April to 1st September 2021, For the period 2nd September to 30th September 2021 with API Holdings Limited.

Intimation of decision taken at the Board Meeting held on December 16, 2021 for approval for sharing certain financial information (Stand-alone and Consolidated) of the Company with API Holdings Limited .

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1^st January, 2022 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter/Nine Months ended December 31, 2021.

Intimation of decision taken at the Board Meeting held on November 13, 2021- (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter /half year ended on 30-09-2021.

Intimation about Board Meeting scheduled to be held on Saturday, November 13, 2021, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / half year ended 30th September 2021

Intimation regarding allotment of 28913 Equity Shares to 158 eligible employees after obtaining required approvals from Stock Exchanges.

The Board of Directors of the Company, at their meeting held on 27th October 2021 has-

1)  Approved the Audited Special Purpose Consolidated financial statements of the Company as on 30^th June 2021, to be included in the DRHP of API Holdings Ltd., who are holding company of Docon Technologies Limited, who are our holding company.

2) Noted the Management Accounts of the Company (unaudited, not reviewed) as on 30^th September 2021 which would be shared with API Holdings Limited and their merchant bankers to give them comfort with respect to their DRHP. This will not be published or shared with any other individual/entity as it might be considered as unpublished price sensitive information.

3)  Approved the proposal, based on the recommendation of the Audit Committee, to enter into an agreement for outsourcing the processing of samples and generating report, with API Holdings Ltd., who are a Related Party under statutory provisions.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1^st October, 2021 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter and half year ended September 30, 2021.

Intimation of decision taken at the Board Meeting held on August 12, 2021- (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter ended on 30-06-2021.

Intimation about Board Meeting scheduled to be held on Thursday, August 12, 2021, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter ended 30th June 2021.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1^st July, 2021 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter ended June 30, 2021.

Intimation about execution of a share purchase agreement dated 25 June 2021 between members of the promoter and promoter group of Thyrocare Technologies Limited (“Company”) (i.e., Dr. A. Velumani, A. Sundararaju HUF, A. Velumani HUF, Amruta Velumani, Anand Velumani, A. Sundararaju, Thyrocare Properties and Infrastructure Private Limited, Pavilion Commercial Private Limited, Thyrocare Publications LLP, Sumathi Infra Project LLP and Mahima Advertising LLP) (“Sellers”) and  Docon Technologies Private Limited (“Acquirer”), the Sellers have agreed to sell to the Acquirer their entire shareholding in the Company, being equivalent to approximately 66.14% of the equity share capital of the Company (on a fully diluted basis) and being equivalent to 3,49,72,999 equity shares of the Company (collectively, the “Sale Shares”), and the Acquirer has agreed to purchase the Sale Shares from the Sellers in accordance with the share purchase agreement, completion of which is subject to certain conditions precedent  (“Share Purchase Agreement”).View Here

Intimation about (i) 21st  Annual General Meeting convened to be held on Saturday, June 26, 2021 at 3.00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) & (ii) E-voting facility available to the Shareholders prior to the AGM and during the AGM.

Intimation of decisions taken at the Board Meeting held on May 8, 2021, about approval of the Audited Financial Statements (both Stand-alone and Consolidated) for the quarter and the whole year ended 31-03-2021, Recommendation of a Dividend of Rs.15/- per share for 2020-21 and granting of Stock Options to the eligible employees of the Company for the year 2020-21.